- Home
- PHGE vs LGVN Comparison
PHGE vs LGVN Comparison
Compare PHGE & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- LGVN
- Stock Information
- Founded
- PHGE 2015
- LGVN 2014
- Country
- PHGE Israel
- LGVN United States
- Employees
- PHGE N/A
- LGVN N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- PHGE Health Care
- LGVN Health Care
- Exchange
- PHGE Nasdaq
- LGVN Nasdaq
- Market Cap
- PHGE 15.5M
- LGVN 16.4M
- IPO Year
- PHGE N/A
- LGVN 2021
- Fundamental
- Price
- PHGE $0.58
- LGVN $0.90
- Analyst Decision
- PHGE Strong Buy
- LGVN Strong Buy
- Analyst Count
- PHGE 1
- LGVN 2
- Target Price
- PHGE $15.00
- LGVN $6.50
- AVG Volume (30 Days)
- PHGE 397.5K
- LGVN 511.3K
- Earning Date
- PHGE 11-13-2025
- LGVN 11-11-2025
- Dividend Yield
- PHGE N/A
- LGVN N/A
- EPS Growth
- PHGE N/A
- LGVN N/A
- EPS
- PHGE N/A
- LGVN N/A
- Revenue
- PHGE N/A
- LGVN $2,073,000.00
- Revenue This Year
- PHGE N/A
- LGVN N/A
- Revenue Next Year
- PHGE N/A
- LGVN N/A
- P/E Ratio
- PHGE N/A
- LGVN N/A
- Revenue Growth
- PHGE N/A
- LGVN 68.67
- 52 Week Low
- PHGE $0.34
- LGVN $0.63
- 52 Week High
- PHGE $1.16
- LGVN $2.48
- Technical
- Relative Strength Index (RSI)
- PHGE 53.87
- LGVN 59.33
- Support Level
- PHGE $0.55
- LGVN $0.75
- Resistance Level
- PHGE $0.63
- LGVN $0.85
- Average True Range (ATR)
- PHGE 0.05
- LGVN 0.06
- MACD
- PHGE -0.00
- LGVN 0.01
- Stochastic Oscillator
- PHGE 35.85
- LGVN 61.60
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.